Skip to Content
Explore different treatments for your high cholesterol >

Namzaric (donepezil / memantine) Disease Interactions

There are 7 disease interactions with Namzaric (donepezil / memantine):

Major

Cholinesterase Inhibitor (Includes Namzaric) ↔ Bradycardia

Severe Potential Hazard, High plausibility

Applies to: Heart Block, Arrhythmias

Due to their pharmacological action, cholinesterase inhibitors can have a vagotonic effect on the sinoatrial and atrioventricular nodes producing bradycardia or heart block. Therapy with cholinesterase inhibitors should be administered cautiously in patients with preexisting bradycardia or underlying cardiac conduction abnormalities. Syncopal episodes have been reported in patients with and without cardiac abnormalities. Atropine may be used to reverse bradycardia produced by cholinesterase inhibitors.

References

  1. "Product Information. Phospholine iodide (echothiophate iodide)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  2. "Product Information. Humorsol Ophthalmic Solution (demecarium bromide ophthalmic)." Merck & Co, Inc, West Point, PA.
  3. "Product Information. Eserine (physostigmine ophthalmic)." Ciba Vision Ophthalmics, Duluth, GA.
View all 11 references
Major

Cholinesterase Inhibitor (Includes Namzaric) ↔ Bronchospasm

Severe Potential Hazard, High plausibility

Applies to: Chronic Obstructive Pulmonary Disease, Asthma

Cholinesterase inhibitors inhibit the hydrolysis of acetylcholine. The enhanced effect of acetylcholine produces constriction of the bronchi, increased bronchial secretions, and bronchospasm. Therapy with cholinesterase inhibitors should be administered cautiously in patients with respiratory dysfunction, history of asthma or obstructive pulmonary disease. Monitoring respiratory function during dosage initiation and adjustment are recommended. Use of atropine along with discontinuation of the cholinesterase inhibitor may be required for serious respiratory distress. Neostigmine may produce more severe muscarinic side effects than does pyridostigmine and ambenonium. However, the duration of action is longest for ambenonium and shortest for edrophonium. Echothiophate iodide ophthalmic may be systemically absorbed and cautious use is recommended in these patients.

References

  1. "Product Information. Humorsol Ophthalmic Solution (demecarium bromide ophthalmic)." Merck & Co, Inc, West Point, PA.
  2. "Product Information. Eserine (physostigmine ophthalmic)." Ciba Vision Ophthalmics, Duluth, GA.
  3. "Product Information. Aricept (donepezil)." Pfizer US Pharmaceuticals, New York, NY.
View all 8 references
Major

Cholinesterase Inhibitor (Includes Namzaric) ↔ Parkinsonism

Severe Potential Hazard, High plausibility

Applies to: Parkinsonism

Cholinesterase inhibitors should be used with caution in patients with parkinsonism. Some of these drugs might be contraindicated in these patients (refer to specific prescribing information). Symptoms of Parkinson's disease may be exacerbated with the increase in cholinergic activity. Caregivers and patients should be advised.

References

  1. "Product Information. Cognex (tacrine)." Parke-Davis, Morris Plains, NJ.
  2. "Product Information. Humorsol Ophthalmic Solution (demecarium bromide ophthalmic)." Merck & Co, Inc, West Point, PA.
  3. el-Yousef MK, Janowsky D, Davis JM, Sekerke HJ "Reversal of antiparkinsonian drug toxicity by physostigmine: a controlled study." Am J Psychiatry 130 (1973): 141-5
View all 7 references
Major

Cholinesterase Inhibitor (Includes Namzaric) ↔ Pud

Severe Potential Hazard, High plausibility

Applies to: Peptic Ulcer

The use of cholinesterase inhibitors is associated with an increase in gastric acid secretion and gastric contractions. Therapy with cholinesterase inhibitors should be administered cautiously in patients with peptic ulcer disease.

References

  1. "Product Information. Prostigman (neostigmine)." ICN Pharmaceuticals Inc, Cost Mesa, CA.
  2. "Product Information. Cognex (tacrine)." Parke-Davis, Morris Plains, NJ.
  3. "Product Information. Humorsol Ophthalmic Solution (demecarium bromide ophthalmic)." Merck & Co, Inc, West Point, PA.
View all 7 references
Major

Cholinesterase Inhibitor (Includes Namzaric) ↔ Seizures

Severe Potential Hazard, Moderate plausibility

Applies to: Seizures

Cholinesterase inhibitors have been associated with convulsions and tremor. Therapy with cholinesterase inhibitors should be administered cautiously in patients with seizure disorders.

References

  1. "Product Information. Prostigman (neostigmine)." ICN Pharmaceuticals Inc, Cost Mesa, CA.
  2. "Product Information. Cognex (tacrine)." Parke-Davis, Morris Plains, NJ.
  3. Stewart GO "Convulsions after physostigmine." Anaesth Intensive Care 7 (1979): 283
View all 8 references
Moderate

Memantine (Includes Namzaric) ↔ Hepatic Impairment

Moderate Potential Hazard, Moderate plausibility

Applies to: Liver Disease

Memantine should be used with caution in patients with severe hepatic impairment and a dosage reduction is recommended. No dosage adjustment is needed in patients with mild or moderate hepatic impairment.

Moderate

Memantine (Includes Namzaric) ↔ Renal Impairment

Moderate Potential Hazard, Moderate plausibility

Applies to: Renal Dysfunction, Urinary Tract Infection

Memantine renal clearance involves active tubular secretion moderated by pH dependent tubular reabsorption and conditions that raise urine pH may increase the plasma levels of memantine. Therapy with memantine should be used cautiously in patients with conditions that raise urine pH, such as renal tubular acidosis or severe infections of the urinary tract. Additionally, memantine should be used with caution in patients with severe renal impairment and a dosage reduction is recommended. No dosage adjustment is needed in patients with mild or moderate renal impairment.

Namzaric (donepezil / memantine) drug Interactions

There are 777 drug interactions with Namzaric (donepezil / memantine)

Namzaric (donepezil / memantine) alcohol/food Interactions

There is 1 alcohol/food interaction with Namzaric (donepezil / memantine)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.

Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2016 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide